VBI Vaccines Inc.
VBIV · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 2.70 | 0.00 | -0.01 |
| FCF Yield | -78.45% | -81.55% | -57.25% | -68.00% |
| EV / EBITDA | -3.46 | -3.65 | -1.62 | -1.62 |
| Quality | ||||
| ROIC | -24.35% | -19.34% | -13.45% | -57.21% |
| Gross Margin | -124.38% | -300.59% | 61.88% | -383.75% |
| Cash Conversion Ratio | 0.66 | 869.29 | 0.39 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 174.30% | 139.62% | 124.90% | 26.11% |
| Free Cash Flow Growth | -4.02% | -41.95% | 58.08% | 13.20% |
| Safety | ||||
| Net Debt / EBITDA | -2.48 | -2.47 | -0.83 | -0.86 |
| Interest Coverage | -5.84 | -5.98 | -4.89 | -18.41 |
| Efficiency | ||||
| Inventory Turnover | 0.27 | 0.40 | 0.33 | 0.51 |
| Cash Conversion Cycle | 164.08 | 188.26 | 70.91 | 194.41 |